SCHEMBL3033628

SCHEMBL3033628

CCC(=O)c1cccc(CC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.50
KAT6A Q92794 2/20 0.48
SMYD3 Q9H7B4 1/20 0.48
CNR2 P34972 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.47
CYP4F2 P78329 3/20 0.46
CYP4A11 Q02928 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
FOLH1 Q04609 1/20 0.44
ATM Q13315 1/20 0.43
PTGS2 P35354 1/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8580572 0.88 PRSS1 (0.46) LOXL2CYP4F2CYP4A11SMN1; SMN2MAPT
SCHEMBL924897 0.86 CYP4F2 (0.49) BCL2KAT6ASMYD3CNR2LOXL2
SCHEMBL6671053 0.86 PRSS1 (0.52) SMYD3CNR2LOXL2CYP4F2CYP4A11
SCHEMBL14982177 0.85 SMYD3 (0.50) BCL2KAT6ASMYD3CNR2LOXL2
SCHEMBL10389972 0.85 SMN1; SMN2 (0.54) SMN1; SMN2MAPTL3MBTL1NPC1HPGD
SCHEMBL4344951 0.85 GSK3B (0.53) BCL2KAT6ASMYD3CNR2LOXL2
SCHEMBL8744793 0.85 LOXL2 (0.53) BCL2KAT6ASMYD3CNR2LOXL2
SCHEMBL10277090 0.85 HPGD (0.49) BCL2KAT6ASMYD3CNR2LOXL2
SCHEMBL30988817 0.85 GSK3B (0.53) BCL2KAT6ASMYD3CNR2LOXL2
SCHEMBL16581153 0.85 FOLH1 (0.50) BCL2KAT6ASMYD3CNR2LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119330913-A Preparation method of eperisone hydrochloride 康普药业股份有限公司 2025-01-21 CN disclosed
CN-117534634-A Preparation method of eperisone hydrochloride 湖南九维生物医药有限公司 2024-02-09 CN disclosed
CN-117250289-A Method for detecting content of p-methyl propiophenone in sample 湖南新领航检测技术有限公司 2023-12-19 CN disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
WO-2021085321-A1 RESIN COMPOSITION, RESIN SHEET, CURED FILM, METHOD FOR MANUFACTURING CURED FILM, SEMICONDUCTOR DEVICE, ORGANIC EL DISPLAY DEVICE, AND DISPLAY DEVICE 東レ株式会社 2021-05-06 WO disclosed
US-20190134005-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARM INC (US) 2019-05-09 US disclosed
EP-2927218-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2018-07-04 EP disclosed
US-9725423-B2 Tetrazolinone compound and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-08 US disclosed
CN-104822666-B Terazololine-one compound and application thereof 住友化学株式会社 2016-09-21 CN disclosed
CN-104411709-B Can be used as imidazo [2, the 1] thiazole-3-ketone derivatives of the diagnostic agent of Alzheimer 霍夫曼-拉罗奇有限公司 2016-08-24 CN disclosed
EP-1740576-B1 NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
EP-1594497-B1 SULFHYDANTOINS AS PHOSPHATE ISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS VERTEX PHARMA (US) 2009-05-27 EP disclosed
CN-100482651-C Diaminothiazoles HOFFMANN LA ROCHE (CH) 2009-04-29 CN disclosed
WO-2007139856-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 WO disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents BRACCO IMAGING SPA (IT) 2007-11-08 US disclosed
CN-1487927-A Diaminothiazoles - 2004-04-07 CN disclosed
US-4487772-A CARDIOTONIC AGENTS OTSUKA PHARMACEUTICAL CO. LTD. (JP) 1984-12-11 US disclosed
US-4468402-A Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-08-28 US disclosed
US-4454130-A CARDIOTONIC, HYPOTENSIVE AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT BCL2 4755/4885KAT6A 1992/4885SMYD3 3268/4885
US-20190134005-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE UGCG, MAN2B1, GBA1 BCL2 3278/4885KAT6A 845/4885SMYD3 420/4885
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents RXFP1, SLC5A7, SLC40A1 BCL2 4697/4885KAT6A 1508/4885SMYD3 1137/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 BCL2 1032/4885KAT6A 1140/4885SMYD3 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.